Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.23M | 775.30K | 306.39K | 90.03K | 13.43K |
Gross Profit | 1.23M | 775.30K | -882.03K | 90.03K | 13.43K |
EBITDA | -25.62M | -34.04M | -29.24M | -25.69M | -19.23M |
Net Income | -26.97M | -35.32M | -30.27M | -26.97M | -20.48M |
Balance Sheet | |||||
Total Assets | 9.40M | 27.95M | 18.30M | 27.49M | 26.15M |
Cash, Cash Equivalents and Short-Term Investments | 3.26M | 20.73M | 10.87M | 20.58M | 19.44M |
Total Debt | 5.82M | 5.86M | 4.97M | 4.02M | 4.44M |
Total Liabilities | 35.51M | 36.66M | 21.42M | 9.77M | 9.86M |
Stockholders Equity | -24.91M | -7.80M | -2.57M | 17.94M | 16.34M |
Cash Flow | |||||
Free Cash Flow | -26.47M | -19.15M | -16.85M | -21.83M | -18.41M |
Operating Cash Flow | -25.89M | -18.06M | -15.28M | -20.85M | -16.46M |
Investing Cash Flow | -573.85K | -1.08M | -1.57M | -973.56K | -1.65M |
Financing Cash Flow | 8.66M | 28.98M | 6.94M | 22.86M | 20.62M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $76.43M | ― | 138.92% | ― | 64.15% | 41.65% | |
54 Neutral | $35.76M | ― | -13.95% | ― | ― | ― | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
51 Neutral | $88.67M | ― | -37.15% | ― | -0.26% | 60.09% | |
50 Neutral | $9.76M | ― | -290.85% | ― | 78.40% | 22.41% | |
45 Neutral | $52.76M | ― | -1454.41% | ― | 35.76% | 47.48% | |
41 Neutral | $11.87M | ― | -127.82% | ― | -24.04% | 84.11% |
At the Annual Meeting on June 18, 2025, VolitionRX‘s stockholders voted on four proposals. The stockholders elected eight members to the Board of Directors, ratified the selection of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm, approved the compensation of the company’s named executive officers, and approved an amendment to the Restated Certificate.
The most recent analyst rating on (VNRX) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.